The Pharmaceutical Research and Manufacturers of America (PhRMA) association surveys its members annually and it explores the trend in PhRMA members’ total expenditure on R&D. Total R&D expenditure from 2009 to 2016 by these pharmaceutical companies showed average growth rates of 5% per annum. Much of that can be contributed to the significant growth in most recent years, with double-digit growth per year since 2014. The R&D intensity (that is, UK R&D expenditure as a share of UK sales) s also steadily increasing, reaching 20.4% in 2016.
The survey also explores the R&D expenditure of PhRMA members which is spent in the US (PhRMA US R&D), generally by leading global multinational pharmaceutical companies. For this group of companies, the US retains the great majority of R&D expenditure and, in 2015, the data indicated that this US share is increasing (3% average annual growth across the 6 years of data).